Table 1

Clinical and genetic characteristicsa

CharacteristicAll patientsGemcitabine plus cisplatinGemcitabine plus cisplatin plus vinorelbineGemcitabine plus vinorelbine–vinorelbine plus ifosfamide
No. of patients8121 (25.9)31 (38.3)29 (35.8)
Age, yr (range)59 (37–75)61 (45–75)57.4 (37–75)60.3 (48–73)
Sex
 Male77 (95.1)21 (100)30 (96.8)26 (89.7)
 Female4 (4.9)1 (3.2)3 (10.3)
Performance status
 0–163 (77.8)16 (76.2)24 (77.4)23 (79.3)
 218 (22.2)5 (23.8)7 (22.6)6 (20.7)
Weight loss >5%34 (42)8 (38.1)15 (48.1)11 (37.9)
Histology
 Adenocarcinoma39 (48.1)10 (47.6)13 (41.9)16 (55.2)
 Squamous cell carcinoma39 (48.1)10 (47.6)16 (51.6)13 (44.8)
 Large cell carcinoma3 (3.7)1 (4.8)2 (6.5)
Stage
 IIIB12 (14.8)5 (23.8)5 (16.1)2 (6.9)
 IV69 (85.2)16 (76.2)26 (83.9)27 (93.1)
Metastatic site
 Liver15 (18.5)5 (23.8)5 (16.1)5 (17.2)
 Lung35 (43.2)9 (42.9)14 (45.2)12 (41.4)
 Bone22 (27.2)3 (14.3)8 (25.8)11 (37.9)
 Brain4 (4.9)4 (13.8)
 Adrenal20 (24.7)3 (14.3)9 (45)8 (27.6)
 Skin6 (7.4)3 (14.3)2 (6.5)1 (3.4)
 Lymph node9 (11.1)3 (14.3)3 (9.7)3 (10.3)
 Others8 (9.9)3 (14.3)3 (9.7)2 (6.9)
ERCC1b mRNA, median (range)1.6 (0.6–10.7)1.5 (0.6–3.9)1.7 (0.6–10.7)1.6 (0.7–4.3)
RRM1 mRNA, median (range)1.1 (0.3–6.9)1.3 (0.3–3.5)1.1 (0.3–6.9)0.9 (0.3–4.9)
ERCC1 mRNAb
 ≤1.745 (55.6)13 (61.9)15 (48.4)17 (58.6)
 >1.736 (44.4)8 (38.1)16 (51.6)12 (41.4)
RRM1 mRNAc
 ≤1.446 (63)12 (60)17 (63)17 (65.4)
 >1.427 (37)8 (40)10 (37)9 (34.6)
No. of chemotherapy cycles, median (range)5 (1–7)5 (1–6)4 (1–7)5 (1–7)
  • a Numbers in parentheses indicate percentages except when specified as a range.

  • b ERCC1, excision repair cross-complementing group 1; RRM1, ribonucleotide reductase subunit M1.

  • c Possible discrepancies between numbers of patients may occur because PCR was not amplified in some instances.